Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.33 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.33 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19410171 | 0.85 | ALDH1A1 (0.36) | AKR1B1ALDH1A1ELANEAAK1CYP1A2 | |
| SCHEMBL19410131 | 0.79 | SLC16A3 (0.43) | SLC16A3HTR2CSLC6A4AKR1B1ALDH1A1 | |
| SCHEMBL29774891 | 0.73 | AKR1B1 (0.38) | AKR1B1ALDH1A1ELANE | |
| SCHEMBL19410193 | 0.73 | L3MBTL1 (0.44) | ALDH1A1TPSAB1TPSD1TPSG1 | |
| SCHEMBL28382342 | 0.73 | AKR1B1 (0.34) | AKR1B1ALDH1A1ELANECYP1A2 | |
| SCHEMBL29774853 | 0.71 | AKR1B1 (0.37) | AKR1B1ALDH1A1ELANE | |
| SCHEMBL31189245 | 0.70 | TPSAB1 (0.34) | NPSR1TPSAB1TPSD1TPSG1SYK | |
| SCHEMBL19410144 | 0.70 | TPSAB1 (0.34) | NPSR1TPSAB1TPSD1TPSG1SYK | |
| SCHEMBL19410213 | 0.70 | ALDH1A1 (0.43) | ALDH1A1NPSR1TPSAB1TPSD1TPSG1 | |
| SCHEMBL17369164 | 0.70 | SYK (0.46) | ALDH1A1NPSR1TPSAB1TPSD1TPSG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440097-B1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-23 | — | — | EP | disclosed |
| US-11066445-B2 | Immunomodulators acting as antagonists of PD-1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200172578-A1 | IMMUNOMODULATORS ACTING AS ANTAGONISTS OF PD-1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-04 | — | — | US | disclosed |
| EP-3642220-A1 | IMMUNOMODULATORS ACTING AS ANTAGONISTS OF PD-1 | Bristol-Myers Squibb Company (US) | 2020-04-29 | — | — | EP | disclosed |
| US-10358463-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-23 | — | — | US | disclosed |
| EP-3440097-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS | Bristol-Myers Squibb Company (US) | 2019-02-13 | — | — | EP | disclosed |
| WO-2018237153-A1 | IMMUNOMODULATORS ACTING AS ANTAGONISTS OF PD-1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-27 | — | — | WO | disclosed |
| WO-2017176608-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017176608-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20170283463-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-10-05 | — | — | US | disclosed |
| US-20170283463-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-10-05 | — | — | US | disclosed |
| US-20170283463-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283463-A1 | IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | SLC16A3 3875/4885HTR2C 3952/4885SLC6A4 4705/4885 |
| US-10358463-B2 | Immunomodulators | CD274, PDCD1, PDCD1LG2 | SLC16A3 3875/4885HTR2C 3952/4885SLC6A4 4705/4885 |
| US-20200172578-A1 | IMMUNOMODULATORS ACTING AS ANTAGONISTS OF PD-1 | CD274, PDCD1, PDCD1LG2 | SLC16A3 3333/4885HTR2C 4175/4885SLC6A4 4667/4885 |
| US-11066445-B2 | Immunomodulators acting as antagonists of PD-1 | CD274, PDCD1, PDCD1LG2 | SLC16A3 3386/4885HTR2C 4116/4885SLC6A4 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.